Banks And Discretionary Stocks Lead S&P 500 Higher In Race To 2,700

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary and join the 2,477 subscribers getting it for FREE every day!

Sign-up For My Premium Room

Banks And Discretionary Stocks Lead S&P 500 Higher In Race To 2,700

Do you believe? It would seem this market still has another leg left to go higher, with the push to 2,700 officially on.  We opined last week that hedge fund underperformance coupled with a pullback that was shallower than expected could lead to a market melt-up over the final 5 weeks of the year. It would seem that push is happening, with an S&P 500 up by nearly 1 percent, closing right around 2,627, 73 points, less than 3 percent from 2,700.

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row] Get This In Your E-Mail Subscribe

Today’s rally was undoubtedly not tech or biotech led either, a positive. It means the market is starting to broaden out, and buyers are finding opportunities in other sectors.  It would help to explain why the Nasdaq Composit was up only 35 bps on the day.

Biotech

The Nasdaq Biotech ETF ($IBB) is up just 15 bps and is sitting at $311; the poor performance is partially tied to Regeneron ($REGN), which is trading down over 2 percent on the day. Regeneron carries a 6 percent weighting in the ETF and is the 5th largest component.

The good news for the group is that the ETF continues hold, and a rally from here is likely coming.

Biotech


Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content Is Great For College Students, Non-Professional, and Professional Investors. It is designed to focus on what institutional investors are watching, based on Mike’s 20 plus years of professional analytic, trading, and portfolio management career.

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

We will respond to questions in short order and will respond to questions with full-post or video segment, just not one or two-word answers. 

Just $40 per Month

Why The S&P500 Could Melt-Up Into Year End

S&P 500 Breakout- 2700?

Nailing The Biotech Breakout

 


 Technology

Surprisingly technology stocks performed poorly by today’s standards, with the Technology ETF ($XLK) up about 25 bps, with the ETF now at $64.70. Apple ($AAPL), Facebook ($FB) and Alphabet ($GOOGL) are three notable laggers; all three are DOWN on the day. High flying Nvidia ($NVDA) is also down on the day, as well as Broadcom ($AVGO).  Nvidia broke a trendline today, probably not catastrophic, but it could mean more selling is on the way.

NVIDIA

Perhaps, some profit taking? There is no doubt that all of the stocks mentioned above are some of the best performing names in the market this year, and it is profit taking season.

NVDA Chart

NVDA data by YCharts

Consumer Discretionary Stocks

Netflix ($NFLX), a consumer discretionary stock, is up by 2 percent and is helping to lead the group higher which is a good reason why the Consumer Discretionary ($XLY) is up over 1 percent trading at nearly $96, we noted the setup for the breakout back on November 10.

Consumer Discretionary

Financials

The Financial ETF ($XLF) rallied by over 2.5 percent today. The bank stocks have been a terrible call all year on my part, every time I think I have it figured out, the opposite happens. The Fed appears to continue to be on pace to keep hiking rates, which is optically considered as a positive for banks because interest income should climb. But remember banks borrow short and lend long, and while the short-end of the curve has been rising all-year, the long-end has not. This is causing the yield curve to contract or flatten. The banks need a round of inflation to get the long-end rising again; otherwise, I’m just not a believer in the banks.  We can see the ETF stopped rising right at resistance today.

But what do I know, I haven’t gotten it right all year.

financials banks stocks

Good Night

Free Articles Written By Mike: 

Why Roku’s Rocketing Stock May Flame Out

Verizon’s Stock May Rise More Than 15% in 2018

Biotechs Celgene, Biogen May Rally Through Yearend

AMD May Have Bottomed, Stock Set to Rise

Macy’s, JC Penney Face More Declines, Options Trades Suggest

Why Tesla’s Plunging Stock Price Conceals A Bright Future

Why Disney and Comcast Should Fear Netflix

We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get all our free commentaries sent directly to your inbox or follow us on Twitter.

-OR-

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”][/vc_column][/vc_row]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capital own shares of GOOGL and NFLX

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #technology #stocks #sp500 #banks #consumer #discretionary #performance #investing

 

[mailpoet_subscribers_count]
2,477
[mailpoet_subscribers_count]
2,477
%d bloggers like this: